Source comparison
CJC-1295 no DAC vs Hexarelin: Research Peptide Comparison
Mechanism Synthetic GHRH analog; amplifies endogenous GH pulses by resisting DPP-IV degradation Synthetic ghrelin mimetic; directly activates GHS-R1a receptors in pituitary and periphery CJC-1295 works with natural pulsatility; Hexarelin bypasses it GH Release
This comparison does not assign a generated winner or score.
- Mechanism
- Synthetic GHRH analog; amplifies endogenous GH pulses by resisting DPP-IV degradation
- Synthetic ghrelin mimetic; directly activates GHS-R1a receptors in pituitary and periphery
- CJC-1295 works with natural pulsatility; Hexarelin bypasses it
- GH Release Pattern
- Sustained 2–4× baseline elevation across 6–8 days per dose
- Acute 5–15× spike at 30–60 min, resolved by 4–6 hours
- CJC-1295 = chronic; Hexarelin = acute
- IGF-1 Elevation
- Sustained 1.5–2.0× baseline for 6–9 days
- Transient or absent unless dosed repeatedly
- CJC-1295 reliably raises IGF-1; Hexarelin requires multi-day protocol
- Receptor Target
- GHRH receptor (pituitary somatotrophs)
- Ghrelin receptor GHS-R1a (pituitary, hypothalamus, heart, periphery)
- CJC-1295 is GH-specific; Hexarelin activates broader targets
- Typical Dosing Frequency
- 2–3× weekly (every 3–7 days)
- Single-dose or daily (study-dependent)
- CJC-1295 suits long protocols; Hexarelin suits acute studies
- Desensitisation Risk
- Minimal (GHRH receptors tolerate pulsatile stimulation)
- High (GHS-R1a desensitises 40–60% after 14 days daily dosing)
- CJC-1295 maintains response; Hexarelin loses efficacy with chronic use
- Non-GH Effects
- None documented
- Cardioprotective (GH-independent), appetite modulation, neuroprotection
- Hexarelin introduces confounding variables; CJC-1295 isolates GH pathway